Stock AnalizViking Therapeutics, Inc. VKTX
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
Viking Therapeutics, Inc. (VKTX) is a healthcare company listed in the US with a market value of about $3.7B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -29%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$360M | -$110M | -$86M | -$69M | -$55M | -$39M | -$26M | -$22M | -$21M | -$15M |
| Free cash flow | — | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | $-3.19 | $-1.01 | $-0.91 | $-0.90 | $-0.71 | $-0.54 | $-0.36 | $-0.38 | $-0.79 | $-0.90 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -48.6% | -13.5% | -22.8% | -37.8% | -21.8% | -13.8% | -9.3% | -6.9% | -89.1% | -96.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 19 analysts is $95.32, 226% above the current price; targets range from $34.00 to $125.00; the consensus rating is “Strong buy”; expected EPS is $-5.31 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Viking Therapeutics pay a dividend?
Not currently.
Is Viking Therapeutics a good stock to buy?
We do not give buy or sell advice. Viking Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.